drugset / Trial / NCT00813124
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2
Completed
24 enrolled
M.D. Anderson Cancer Center
Celgene Corporation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase the likelihood of achieving a complete remission of CML.
Timeline
- Start
- 2008-12
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 32 mg/m2 | Subcutaneous |
| Subject | Busulfan | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | 40 mg/m2 | Intravenous |
| Background | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |